Scribe Therapeutics Inc. (SCTX) vs Sagimet Biosciences Inc. (SGMT)

A side-by-side comparison of Scribe Therapeutics Inc. and Sagimet Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

SCTX

Scribe Therapeutics Inc.

$264M

$16.33HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

SGMT

Sagimet Biosciences Inc.

$286M

$8.78HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — SCTX vs SGMT

growth of $100 · dividends reinvested · last 1y

SCTX +8.1% (+8.1%/yr)SGMT +28.8% (+28.8%/yr)SGMT compounded faster over this window

SCTX SGMT

Metrics side by side

Total return (annualized)

Metric	SCTX	SGMT
Total return (1Y)	N/A	23.74%
Total return CAGR (3Y)	N/A	7.89%

SCTX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full SCTX analysis Full SGMT analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.